Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine

Helen E. Grote*, Natalie D. Bull, Monique L. Howard, Anton Van Dellen, Colin Blakemore, Perry F. Bartlett, Anthony J. Hannan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

152 Citations (Scopus)


Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded CAG trinucleotide repeat encoding an extended polyglutamine tract in the huntingtin protein. Affected individuals display progressive motor, cognitive and psychiatric symptoms (including depression), leading to terminal decline. Given that transgenic HD mice have decreased hippocampal cell proliferation and that a deficit in neurogenesis has been postulated as an underlying cause of depression, we hypothesized that decreased hippocampal neurogenesis contributes to depressive symptoms and cognitive decline in HD. Fluoxetine, a serotonin-reuptake inhibitor commonly prescribed for the treatment of depression, is known to increase neurogenesis in the dentate gyrus of wild-type mouse hippocampus. Here we show that hippocampal-dependent cognitive and depressive-like behavioural symptoms occur in HD mice, and that the administration of fluoxetine produces a marked improvement in these deficits. Furthermore, fluoxetine was found to rescue deficits of neurogenesis and volume loss in the dentate gyrus of HD mice.

Original languageEnglish
Pages (from-to)2081-2088
Number of pages8
JournalEuropean Journal of Neuroscience
Issue number8
Publication statusPublished - Oct 2005
Externally publishedYes


  • Depression
  • Hippocampus
  • Neurodegenerative
  • Serotonin-reuptake inhibitor

Fingerprint Dive into the research topics of 'Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine'. Together they form a unique fingerprint.

Cite this